title: A replication study and a meta-analysis of the association between the CDKN2A rs1333049 polymorphism and coronary heart disease.
abstract: OBJECTIVE
  The aim of this study was to assess whether rs1333049 was associated with coronary heart disease (CHD) in Han Chinese.
  
  
  METHODS
  This case-control study was involved with 599 CHD patients and 591 non-CHD controls. Meanwhile, a comprehensive meta-analysis was also conducted to establish the contribution of rs1333049 to CHD.
  
  
  RESULTS
  Our results showed that rs1333049 increased the risk of CHD by 38% (OR=1.38, 95% CI=1.18-1.62). A breakdown analysis by gender further indicated that rs1333049 increased the risk of CHD in men by 29% (OR=1.29, 95% CI=1.05-1.58) and in women by 64% (OR=1.64, 95% CI=1.25-2.16). A follow-up subgroup analysis by age showed there was a significant association between rs1333049 and CHD in women younger than 65 (≤55 years: p=0.001, 55-65 years: p=0.008) and in men aged between 55 and 65 years (p=0.005). Our meta-analysis was involved with 21 studies (25 stages) among 20969 cases and 34114 controls. Our results showed that rs1333049 led to a significantly increased risk of CHD (OR=1.30, 95% CI=1.21-1.39). Further subgroup analyses by ethnicity showed rs1333049 increased the CHD risk by 30% in Europeans (OR=1.30, 95% CI=1.16-1.47) and 27% in Asians (OR=1.27, 95% CI=1.22-1.33).
  
  
  CONCLUSIONS
  Our case-control study and meta-analysis suggest that rs1333049 is a useful risk marker of CHD.
authors.affiliation: Ningbo Medical Center, Lihuili Hospital, Department of Cardiology, Ningbo University.
authors.forename: Jiangfang
authors.initials: J
authors.lastname: Lian
authors.forename: Yanna
authors.initials: Y
authors.lastname: Ba
authors.forename: Dongjun
authors.initials: D
authors.lastname: Dai
authors.forename: Zhikui
authors.initials: Z
authors.lastname: Chen
authors.forename: Yumei
authors.initials: Y
authors.lastname: Lou
authors.forename: Qingjun
authors.initials: Q
authors.lastname: Jiang
authors.forename: Ruochi
authors.initials: R
authors.lastname: Zhao
authors.forename: Liqin
authors.initials: L
authors.lastname: Sun
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Huang
authors.forename: Xi
authors.initials: X
authors.lastname: Yang
authors.forename: Ming
authors.initials: M
authors.lastname: Ye
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Haiyan
authors.initials: H
authors.lastname: Mao
authors.forename: Haiwang
authors.initials: H
authors.lastname: Guan
authors.forename: Limin
authors.initials: L
authors.lastname: Xu
authors.forename: Jian
authors.initials: J
authors.lastname: Guo
authors.forename: Peiliang
authors.initials: P
authors.lastname: Fang
authors.forename: Junxin
authors.initials: J
authors.lastname: Li
authors.forename: Huadan
authors.initials: H
authors.lastname: Ye
authors.forename: Xiaoliang
authors.initials: X
authors.lastname: Chen
authors.forename: Ping
authors.initials: P
authors.lastname: Peng
authors.forename: Jianqing
authors.initials: J
authors.lastname: Zhou
authors.forename: Shiwel
authors.initials: S
authors.lastname: Duan
mesh_terms: D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D019941:Cyclin-Dependent Kinase Inhibitor p16